Clinical Trials
24 trialsCardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies
Kura Oncology, Inc.
Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer
Kura Oncology, Inc.
Tipifarnib and Radiation Therapy in Treating Patients With Unresectable Locally Advanced Pancreatic Cancer
Abramson Cancer Center at Penn Medicine
R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia
University of Maryland, Baltimore
Tipifarnib Plus Radiation Therapy After Combination Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
Abramson Cancer Center at Penn Medicine
Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer
National Cancer Institute (NCI)
Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia
University Health Network, Toronto
Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
National Cancer Institute (NCI)
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase
National Cancer Institute (NCI)
Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
Emory University
Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Tipifarnib in Treating Patients With Myelodysplastic Syndromes
National Cancer Institute (NCI)
Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
Tipifarnib in Treating Patients With Advanced Hematologic Cancer
National Cancer Institute (NCI)
Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
R115777 Plus Topotecan in Treating Patients With Advanced Solid Tumors
NYU Langone Health
Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Combination Chemotherapy in Treating Patients With Advanced Cancer
The University of Texas Health Science Center at San Antonio
Tipifarnib in Treating Young Patients With Refractory Leukemia
National Institutes of Health Clinical Center (CC)
R115777 in Treating Patients With Advanced Solid Tumors
City of Hope Medical Center
Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)
National Center for Research Resources (NCRR)